FDA accepts IND for Gemini Phase 1b CKD study; REVB raises ~$4.1M from warrant exercises

REVELATION BIOSCIENCES, INC.

FDA accepted IND for Gemini (trained immunity) for Phase 1b study in up to 40 CKD patients; primary endpoint safety/tolerability.
Existing Class E warrants exercised at $1.00/share for ~$4.1M gross proceeds; new Class F and G warrants issued as inducement.
Proceeds to fund clinical trials for GEM-AKI, GEM-CKD, GEM-PSI and working capital.
New Class F warrants (2yr, $1.00) and Class G warrants (5yr, $1.00) subject to stockholder approval; include cashless exercise provisions.

item 1.01 item 3.02 item 3.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.